{"entity":{"id":"paper-destiny-crc01-lancet-oncol-2021","kind":"paper","name":"DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer","aka":[],"tldr":"Trastuzumab deruxtecan shrank tumours in about 45 percent of patients with HER2-high colorectal cancer, including those who had already received other HER2 drugs, but did nothing for tumours with low HER2 expression and carried a risk of lung inflammation.","summary":"Phase 2 study of 86 patients with HER2-expressing, RAS and BRAF wild-type metastatic colorectal cancer after at least two regimens, treated with trastuzumab deruxtecan 6.4 mg/kg in three cohorts by HER2 level.\n\nIn the HER2 immunohistochemistry 3+ or 2+ with amplification cohort, objective response was 45.3 percent with median progression-free survival 6.9 months, including responses after prior HER2 therapy; no responses were seen in the low-expression cohorts, and interstitial lung disease occurred in 9 percent with some deaths.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2021","url":"https://doi.org/10.1016/S1470-2045(21)00086-3"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33961795/"}],"tags":[],"related":[],"cancers":["her2-amplified-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["crc01","trastuzumab","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00086-3","pmid":"33961795","authors":"Siena S, Di Bartolomeo M, Raghav K, et al.","paperType":"observational","findings":["Objective response 45.3 percent in HER2-positive cohort A; median progression-free survival 6.9 months.","No responses in HER2 2+ non-amplified or 1+ cohorts; interstitial lung disease 9.3 percent."],"whatItMeans":"Trastuzumab deruxtecan is an option for HER2-positive colorectal cancer after HER2 antibodies, and it contributed to the tumour-agnostic approval for HER2 3+ solid tumours; lung monitoring is essential.","caveats":["Single-arm; interstitial lung disease including fatal cases.","The 6.4 mg/kg dose is higher than that used in breast cancer."],"changedPractice":true,"participants":86},"route":"/key-papers/paper-destiny-crc01-lancet-oncol-2021/","neighbours":{"cancer":[{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"}],"drug":[{"id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}